IPP Bureau
Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant
By IPP Bureau - September 18, 2024
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Briefs: Eugia Steriles and Shelter Pharma
By IPP Bureau - September 18, 2024
Eugia Steriles receives EIR from USFDA for new injectable facility
Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
By IPP Bureau - September 18, 2024
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Aragen receives SBTi approval for its greenhouse gas emission reduction targets
By IPP Bureau - September 17, 2024
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
Merck and Siemens partner on digital transformation technology
By IPP Bureau - September 17, 2024
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Panacea Biotec and Sanofi reached settlement agreement for Shan6
By IPP Bureau - September 17, 2024
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Alembic appoints Sudhakar Pandiyan as Head - Technical Operations
By IPP Bureau - September 17, 2024
He has been associated with Caplin Steriles Ltd., Mylan Laboratories Ltd., Caplin Point Laboratories Ltd., Strides Arcolab Ltd. and Novartis Vaccines and Diagnostics
Piramal Pharma's GHG Commitment Validated and Approved by SBTi
By IPP Bureau - September 17, 2024
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
By IPP Bureau - September 17, 2024
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
By IPP Bureau - September 16, 2024
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
By IPP Bureau - September 16, 2024
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy
By IPP Bureau - September 16, 2024
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Laurus Labs inaugurates Rs. 250 crore R&D facility in Telangana
By IPP Bureau - September 16, 2024
Total investment incurred for setting up the new R&D Rs 250 crore
Strides receives USFDA approval for Fluoxetine Tabs 60 mg
By IPP Bureau - September 16, 2024
Fluoxetine Tabs 60 mg approval solidifies the company's position in the molecule by complementing the recent approval in April 2024 for Fluoxetine 10 mg and 20 mg tablets and Fluoxetine capsules
Department of Pharmaceuticals continues with special campaign for disposal of pending matters
By IPP Bureau - September 16, 2024
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
